Press Releases and Events
Weight Loss Success and Behavioral Changes Achieved with IntraPace abiliti® System
Data presented at IFSO-EC 2012 show gastric stimulator promotes lifestyle changes that lead to sustained weight loss
Barcelona, Spain and Mountain View, CA, USA - April 27, 2012
The abiliti® implantable weight loss management system has been developed specifically to treat obesity by promoting lifestyle and behavioral changes. Data from a clinical study presented at the 5th Congress of the International Federation for the Surgery of Obesity and Metabolic Disorders European Chapter (IFSO-EC) in Barcelona, Spain, show that the abiliti system supports significant weight loss, is well tolerated and promotes behavioral changes.
The abiliti system combines gastric stimulation, which helps patients feel full sooner, and unique data collection and monitoring tools, to allow patients and doctors to constantly monitor progress (reduction in food intake and amount of exercise) and implement necessary lifestyle changes to maintain sustained weight loss.
“The results of this study show some of the unique attributes of the abiliti system. Not only are patients achieving significant weight loss, they are able to take control and make the necessary lifestyle changes to maintain this weight loss,” noted Dr. Günther Meyer, an investigator in the study and Chief of General Surgery, Wolfart Klinik, Munich, Germany, who presented the data at the IFSO-EC conference. “Unlike other bariatric procedures, the abiliti system provides patients with the added benefit of being able to continuously monitor eating and exercise information on their home computer.”
In the clinical study presented at the conference, the abiliti system was laparoscopically implanted into 31 obese subjects (BMI 35-55). At 12 months, patients on average showed a mean excess weight loss (EWL) of approximately 30%. Analysis of data from two separate patient groups (one with EWL above 25% and one group with EWL below 25% at 12 months) showed that eating habits and exercise had a dramatic impact on sustained weight loss. For the group above 25%, at 12 months, excess weight loss was found to be approximately 44%. This group demonstrated a significant change in behavior, showing a reduction in snacking both during the day and at night. Because the abiliti device records this data automatically, 24 hours a day, doctors receive accurate eating information, as compared to data self-reported by patients, allowing doctors to guide patients on future lifestyle changes that can dramatically impact weight loss goals.
During the IFSO conference today, IntraPace will host a lunch symposium on the abiliti system at the Palacio de Congresos Catalunya (PCC), rooms B2/B3, between 13:45 and 14:45.
About the abiliti System
Following implantation via a simple minimally invasive surgical procedure, the abiliti system detects when a person eats or drinks and sends low-level electrical impulses to the stomach. This stimulation helps a person feel full before the stomach is actually full, causing them to eat less. As the anatomy of the stomach and intestines is not changed, clinical experience with the abiliti system has shown virtually none of the nausea, diarrhea and other side effects seen with gastric bypass surgery and gastric banding. Patients are not restricted in the types of food that they consume, but are encouraged to adopt a healthy diet and exercise program.
Further, this novel system automatically records when a patient eats, drinks and exercises. Using a simple wireless connection, patients and physicians can view the consumption and exercise data. Access to this information provides an important benefit as it allows physicians and patients to understand patient behaviors and develop effective strategies for maintained weight loss. Additionally, the system connects patients to a valuable social support network (my.abiliti.com), which research has demonstrated can increase the effectiveness of weight loss programs.
IntraPace was founded in 2001 to address an unmet need in weight loss surgery by developing a gentler solution for weight loss that incorporates essential components of behavior therapy. The abiliti system enables patients to achieve and sustain significant weight loss without the complications, lifestyle restrictions and substantial anatomical changes associated with the established weight loss surgeries.
Based in Mountain View, California, IntraPace is backed by premier investors, including Boston Scientific, CB Health Ventures, DFJ ePlanet Ventures, InCube Ventures, Johnson & Johnson Development Corp., L Capital Partners, Oxford Bioscience Partners, Toucan Capital Corp, Angels’ Forum, Halo Fund and Vulcan Capital.
The abiliti system has CE Mark in the European Union. It is not approved for sale in the United States. For more information, visit www.abiliti.com.
Christopher Rowland, Chief Commercial Officer
Tel: +1 (650) 316 4075
Tel: +44 (0)20 7318 2959